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Abstract Current pharmacological strategies for Parkin-
son’s disease (PD), the most common neurological move-
ment disorder worldwide, are predominantly symptom
relieving and are often plagued with undesirable side
effects after prolonged treatment. Despite this, they remain
as the mainstay treatment for PD due to the lack of better
alternatives. Nutraceuticals are compounds derived from
natural food sources that have certain therapeutic value and
the advent of which has opened doors to the use of alter-
native strategies to tackle neurodegenerative diseases such
as PD. Notably, nutraceuticals are able to position them-
selves as a ‘‘safer’’ strategy due to the fact that they are
naturally derived compounds, therefore possibly having
less side effects. Significant efforts have been put into
better comprehending the role of nutraceuticals in PD, and
we will look at some of them in this review. Broadly
speaking, these compounds execute their positive effects
via modulating signalling pathways, inhibiting oxidative
stress, inflammation and apoptosis, as well as regulating
mitochondrial homoeostasis. Importantly, we will highlight
how a component of green tea, epigallocatechin-3-gallate
(EGCG), confers neuroprotection in PD via its ability to
activate AMP kinase and articulate how its beneficial
effects in PD are possibly due to enhancing mitochondrial
quality control.
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Introduction
Parkinson’s disease (PD) is the most common neurode-
generative movement disorder currently affecting around
5–6 million predominantly elderly individuals worldwide.
PD is expected to be even more commonplace in the near
future as the world’s population rapidly ages. In 2030,
about 10 million or more are expected to be afflicted with
PD (Dorsey et al. 2007). Clinically, the disease is charac-
terized by a constellation of motoric deficits including
resting tremor, bradykinesia (slowness in movements),
postural instability and rigidity that arises from the deple-
tion of striatal dopamine—a result of the progressive loss
of midbrain dopaminergic neurons in the substantia nigra
pars compacta (SNpc) that innervate the striatum. This is
accompanied by the characteristic neuropathological pat-
tern of eosinophilic intracytoplasmic inclusions known as
Lewy bodies (LBs) in surviving neurons in the SN. Nota-
bly, a-synuclein, a presynaptic protein whose mutations are
causative of familial PD, is a major component of LBs
(Polymeropoulos et al. 1997). Although a small percentage
of PD cases are inheritable as a result of mutations in genes
including a-synuclein, Parkin, LRRK2, PINK1, and DJ-1,
exposure to environmental toxins and pesticides, such as
paraquat and rotenone, and synthetic toxins, such as
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), can
also lead to PD (Goldman 2014). To date, the exact disease
mechanisms underlying PD pathogenesis are not fully
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understood, but studies have consistently implicated aber-
rant mitochondrial and protein homoeostasis as key con-
tributors to the development of PD, with oxidative stress
likely acting as an important nexus (Lim and Zhang 2013).
At present, therapeutic strategies for the PD patient
remain largely symptomatic and more often than not,
existing pharmacological treatments come with undesirable
side effects. Indeed, pharmacological replacement of
dopamine with L-Dopa remains as the gold standard for PD
treatment despite its association with diminishing effects
and problematic drug-induced dyskinesia after prolonged
intake. These inadequacies of the gold standard treatment
highlight an urgent need to develop more effective disease-
modifying drugs for PD. In recent years, several alternative
approaches to delay the progression of the disease have
been considered and coming under the spotlight recently is
nutraceuticals. Functional foods and nutritional supple-
ments, which are common sources of nutraceuticals, are
beginning to gain international recognition due to the
potential health benefits they harbour when consumed as
part of a varied diet on a regular basis and at optimal levels.
Consequently, both the scientific community and food
industry are motivated to exploit these benefits for the
prevention and even treatment of chronic ageing diseases,
including PD.
Nutraceuticals and PD
As the word suggests, ‘‘nutraceuticals’’ refers to com-
pounds that are derived from natural sources, and these
food or derivatives therein have been clinically substanti-
ated with reasonable scientific evidence to support their
beneficial role in the prevention and/or treatment of a
particular disease (Chao et al. 2012). It is this very reason
that nutraceuticals are more readily accepted by the general
populace as a form of treatment. There is a greater ten-
dency to believe that there are fewer side effects associated
with compounds derived from natural sources as compared
to the many known side effects of synthetic drug
compounds.
In the context of PD, several nutraceuticals have been
shown to provide neuroprotection in experimental models
and may serve as alternatives to synthetic drug compounds
like L-Dopa that is known to cause many undesirable side
effects. The mechanisms by which they work can be
broadly classified into the following themes: (1) reactive
oxygen species (ROS)/free radical scavenging; (2) anti-
inflammation; (3) iron chelation; (4) modulation of cell
signalling pathways; (5) anti-apoptosis; and (6) mitochon-
drial homoeostasis, although several nutraceuticals essen-
tially function via a myriad of mechanistic pathways rather
than adhere to a single mechanism (Fig. 1). Table 1
summarizes existing nutraceuticals that have been found to
confer neuroprotection in PD. We will discuss a few
examples of these below.
The seeds of the Mucuna plant, also affectionately
known as dopa bean, are well known for containing L-
Dopa, the go-to drug for treating PD. Although some
species of Mucuna contain more L-Dopa than others, the
Mucuna plant is generally favoured for the exploitation of
L-Dopa due to its relative abundance of which compared to
other plant families that have been studied (Patil et al.
2015). Other microbial and chemical means of synthesizing
L-Dopa have also been explored (Surwase et al. 2012;
Krishnaveni et al. 2009; Ali et al. 2007; Sikander and
Ikram ul 2006), but the Mucuna plant has been preferred as
it is a natural and inexpensive source, and it provides
additional benefits as an antioxidant (Manyam et al. 2004).
In fact, a species of Mucuna plant, Mucuna pruriens, has
been shown in both the PD mice model and patients to be
more effective than L-Dopa without the accompanying
increase in dyskinesia (Hussian and Manyam 1997;
Katzenschlager et al. 2004).
Apart from the Mucuna plants, there are many other
nutraceuticals that appear to be neuroprotective due to
their anti-oxidative properties. Such properties are par-
ticularly important in the context of PD as several studies
have pointed to oxidative stress, which results in ROS
generation and inflammation, as a pivotal contributor to
age-related neuronal loss in PD (Jenner 1998). An
example of a nutraceutical that possesses both anti-ox-
idative and anti-inflammatory properties is ginsenoside, a
phytoestrogen that is extracted from several species of
ginseng (Chen et al. 2005). It executes its anti-oxidative
properties by maintaining glutathione levels, and its anti-
inflammatory properties are a result of the regulation of
several inflammatory pathways including the ROS-NFjB,
JNK, P13K/AKT, ERK, IGF-1 receptor signalling path-
ways and oestrogen receptor pathway. In addition, gin-
senoside also reduces the levels of nigral iron of MPTP-
treated mice by regulating the expression of iron transport
proteins (Wang et al. 2009b). This is of importance as the
build-up of iron in conjunction with ROS at the site of
neurodegeneration is thought to constitute a major trigger
in neurotoxicity and neuronal demise in PD (Zecca et al.
2004). As such, nutraceuticals like ginsenoside that can
inhibit pro-inflammatory and oxidative processes should,
in theory, be able to attenuate dopaminergic neuronal
damage. Indeed, it has been demonstrated that gin-
senoside protects against toxicities and dopaminergic
neuronal loss induced by PD toxins including 6-hydrox-
ydopamine (6-OHDA) and MPTP (Chen et al. 2005; Xu
et al. 2009). Due to its role in the regulation of JNK
signalling, ginsenoside also possesses anti-apoptotic
properties. Hence, another postulated mechanism through
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which the neuroprotective effect of ginsenoside is facili-
tated is its reduction of c-Jun phosphorylation, which
prevents pro-apoptotic JNK signalling and dopaminergic
neuronal loss during MPTP-induced neurotoxicity (Leppa
and Bohmann 1999).
Besides ginseng, dietary soy and peanut products have
also been reported to have similar anti-apoptotic effects.
Soy and peanut are rich sources of genistein, a phytoe-
strogen-like ginsenoside. Genistein acts as a tyrosine
kinase inhibitor that attenuates protein kinase C (PKC)
activation and thereby downstream apoptotic effects (Kaul
et al. 2005; Baluchnejadmojarad et al. 2009). Another
potent anti-apoptotic nutraceutical that has been shown to
protect against PD toxin-induced neurotoxicity is Ginko-
biloba extract EGb 761. EGb 761 prevents the formation
of apoptosome and the apoptotic cascade by blocking
cytochrome-c release (Liu et al. 2008; Yeh et al. 2009;
Nevado et al. 2010). Like ginsenoside, EGb 761 also
attenuates the phosphorylation of c-Jun (Shi et al. 2009)
and furthermore inhibits the cleavage of caspase-3 (Liu
et al. 2008; Shi et al. 2009), thereby preventing DNA
fragmentation, a hallmark of apoptosis. By blocking
apoptosis through various mechanistic pathways, genistein
and EGb 761 were found to attenuate dopaminergic
neuronal loss and reduce associated locomotion impair-
ment in 6-OHDA and MPTP mice models (Ahmad et al.
2005; Baluchnejadmojarad et al. 2009; Rojas et al. 2012;
Yang et al. 2001).
Nutraceuticals and Mitochondrial Homoeostasis
As mentioned earlier, aberrant mitochondrial homoeostasis
is commonly implicated in PD pathogenesis. Intuitively,
one would propose that nutraceuticals that have a role in
mitochondrial regulation can potentially mitigate PD
pathology. Coenzyme Q10 (CoQ10) is a component of the
mitochondrial electron transport chain and participates
actively in ATP generation. It is noteworthy to mention
that in PD animal models, CoQ10 attenuates MPTP-induced
neurotoxicity, possibly due to its unique electron-accepting
property, rendering it critical to the electron transfer
between mitochondrial complex 1 and other complexes of
the electron transport chain (Beal et al. 1998; Cleren et al.
2008). Although it has been proposed as a therapeutic
strategy for PD (Shults 2005), clinical trials involving
CoQ10 have been conflicting. While one study by Shults
et al. reported a dose-dependent reduction in functional
decline, another study by Muller et al. observed only mild
symptomatic benefit (Shults et al. 2002; Muller et al.
2003). Other nutraceuticals that are reported to be neuro-
protective due to their role in preserving mitochondrial
complex 1 activity include curcuminoids from turmeric
(Jagatha et al. 2008) and the earlier-mentioned Mucuna
plant (Manyam et al. 2004). Yet another key player in the
maintenance of ATP levels is phosphocreatine, an energy
reserve in skeletal muscles and brain. Notably, treatment
with creatine appears to rescue parkinsonian phenotypes in
Fig. 1 Nutraceuticals as
therapeutics for PD.
Nutraceuticals for PD can be
grouped broadly into six themes
based on their neuroprotective
properties: (1) iron chelation;
(2) cell signalling modulation;





properties and function via a
myriad of mechanistic pathways
rather than adhere to a single
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both human subjects and animal models. Specifically, diet
supplement of creatine was found to improve the mood and
reduce the dosages required for dopamine (DA) replace-
ment therapy in PD patients (Bender et al. 2006), as well as
reduce dopaminergic neuronal loss in SNpc of MPTP-
treated mice (Matthews et al. 1999). It certainly seems that
mitochondrial homoeostasis is a common targeted pathway
for nutraceutical therapy notwithstanding the controversy
surrounding CoQ10.
Epigallocatechin-3-gallate (EGCG), a main green tea-
derived catechin, is a nutraceutical that is frequently fea-
tured in PD, perhaps due to its numerous putative neuro-
protective mechanisms that is not limited to mitochondrial
homoeostasis (Pan et al. 2003). These include anti-oxida-
tion, iron chelation, ROS scavenging and anti-apoptotic
properties. Moreover, EGCG crosses the blood–brain bar-
rier easily, making it an attractive compound for therapy.
Besides the myriad of properties, EGCG has been reported
to be an AMPK activator (Spasic et al. 2009; Hwang et al.
2009). It increases cytosolic Ca2? levels, thereby influ-
encing the activity of Ca2?-/calmodulin-dependent protein
kinase kinase (CaMKKb), an upstream kinase of AMPK
(Kim et al. 2014). The activation of AMPK in the presence
of EGCG is therefore likely to be mediated by CaMKKb.
As discussed below, AMPK activation by EGCG has been
demonstrated to be neuroprotective.
AMPK Activation and Neuroprotection
AMPK is a central energy sensor and regulator that is
normally activated in response to diminishing energy
supply, e.g. ATP depletion or glucose starvation (Li et al.
2012). Given the critical role of AMPK in energy
homoeostasis, it is perhaps not surprising to note that
AMPK has profound influence on mitochondrial
homoeostasis amidst a plethora of metabolic events that it
governs. It is well documented that AMPK works through
peroxisome proliferator-activated receptor gamma coacti-
vator 1-alpha (PGC-1a) to promote mitochondrial bio-
genesis (Lee et al. 2012). Although the mechanism by
which AMPK upregulates PGC-1a activity remains
unclear, studies have suggested that it could directly
phosphorylate PGC-1a (Ng et al. 2012b) or indirectly
activate the transcriptional coactivator by promoting its
deacetylation through the NAD?-dependent deacetylase
SIRT1 (Ng et al. 2012b). Interestingly, a recently identified
AMPK target is UNC-51-like kinase 1 (ULK1), a mam-
malian ortholog of the yeast Atg1 kinase that acts as a key
initiator of the autophagy cascade (Carroll et al. 2014;
Martin et al. 2014). The activation of ULK1 by AMPK
promotes autophagy, including mitophagy. Accordingly,
when ULK1 function is impaired, it results in the
accumulation of abnormal mitochondria with reduced
potential (Martin et al. 2014). Similarly, when the known
AMPK-mediated phosphorylation sites on ULK1 are
abolished, autophagy is also impaired (Martin et al. 2014),
suggesting that the clearance of damaged mitochondria is
dependent on the AMPK–ULK1–autophagy pathway.
More recently, a study by Toyama et al. reported that
AMPK is required for rotenone-induced mitochondrial
fission (Toyama et al. 2016), an essential process to isolate
damaged mitochondria and promote mitophagy (Twig et al.
2008). Importantly, they identified a novel substrate of
AMPK, mitochondrial fission factor (MFF), and found that
the presence of non-phosphorylatable MFF resulted in
defective mitochondrial fission, further emphasizing the
importance of AMPK in regulating mitophagy.
Notwithstanding earlier discussion that AMPK activa-
tion helps to maintain mitochondrial quality control and
should theoretically promote cellular survival, the role of
AMPK activation in neuroprotection remains controversial.
Similarly, AMPK activation is also a double-edge sword in
the case of PD, promoting neurodegeneration under some
circumstances yet aggravating in others. For instance, a
study by Kim et al. contradicts a neuroprotective role of
AMPK in PD and found that AMPK mediates dopamin-
ergic neuronal atrophy in 6-OHDA-lesioned mice. More-
over, metformin-induced AMPK activation accelerates
rather than retards 6-OHDA-induced neuronal loss in these
mice (Kim et al. 2013). Subsequently, Xu et al. also
observed in a related study similar detrimental effects of
AMPK activation in primary neurons treated with
6-OHDA, MPTP or rotenone (Xu et al. 2014). Nonetheless,
there are also several reports supporting a neuroprotective
role of AMPK in PD. In a recent study by Patil et al.,
MPTP-treated mice on chronic metformin regimen
demonstrated enhanced antioxidant activity and brain-
derived neurotrophic factor (BDNF) levels, thereby ren-
dering protection against dopaminergic neuronal loss
induced by MPP? (Patil et al. 2015). In a related study,
AMPK is activated upon MPTP treatment, and when
AMPK activity is downregulated by compound C, neuro-
toxicity is enhanced (Choi et al. 2010). Supporting this, a
recent study demonstrated similar findings albeit in cul-
tured cells exposed to rotenone (Wu et al. 2011). Given that
both MPP ? and rotenone are complex I inhibitors, the
rescue of the in vivo and in vitro PD models by AMPK
activation is consistent with its role in the maintenance of
mitochondrial homoeostasis. Importantly, it is also note-
worthy to mention that a recent cohort-based study
involving 800,000 subjects in a Taiwanese population
revealed that metformin-inclusive sulfonylurea therapy
significantly reduces PD risk in individuals with type 2
diabetes (Wahlqvist et al. 2012), suggesting the neuropro-
tective effects of AMPK activation. Collectively, these
Neuromol Med (2016) 18:306–321 315
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findings suggest that AMPK activation may be beneficial
for the disease.
On a related note, we have recently found that EGCG
facilitates neuroprotection in PD by mediating mitochon-
drial regulation via AMPK activation. Using Drosophila as
a model, we found that EGCG administration ameliorates
the pathological phenotypes of parkin null PD flies,
including prominent mitochondrial abnormalities and pro-
gressive loss of selected dopaminergic neuronal clusters
that are accompanied by an age-dependent decline in
locomotor ability (Ng et al. 2012a). These are disease
phenotypes that bear resemblance to that of human PD
(Green and Kroemer 2004; Whitworth et al. 2005).
Importantly, the EGCG-mediated protective effects require
AMPK as genetic inactivation of AMPK abolishes the
neuroprotective effects while subsequent genetic restora-
tion of AMPK and pharmacological activation of AMPK
with potent AMPK activators (metformin or AICAR)
reproduce these beneficial effects (Ng et al. 2012a). In
contrast, treatment of parkin null flies with another com-
pound, i.e. Baicalein—an established antioxidant (Shieh
et al. 2000), failed to ameliorate the observed parkinsonian
phenotypes (unpublished observation). Accordingly, we
speculated that AMPK activation rather than anti-oxidation
may be involved in EGCG-mediated protective effects. In a
similar fashion, Drosophila LRRK2 mutants could be rid
of its pathological phenotypes via pharmacological treat-
ment with EGCG, metformin or AICAR or the co-ex-
pression of a constitutively active AMPK mutant (Ng et al.
2012a), suggesting that this approach may be relevant to
different forms of PD. Consistent with our results, Ferretta
et al. demonstrated similar benefits using resveratrol (Fer-
retta et al. 2014), another nutraceutical found in the skin of
grapes and berries that is known to be a relatively strong
AMPK activator (Dasgupta and Milbrandt 2007). In
patient’s fibroblasts harbouring parkin mutations, they
found that resveratrol increased mitochondrial biogenesis
and improved oxidative phosphorylation (Ferretta et al.
2014).While AMPK activation brings about a virtually
complete rescue of PD pathological phenotypes in flies, we
are currently on the endeavour to dissect precisely how it
happens. Nevertheless, existing knowledge of AMPK has
shed light on the possible mechanistic pathways via which
AMPK-mediated neuroprotection may occur. As men-
tioned earlier, AMPK is capable of positively regulating
mitochondrial biogenesis via PGC-1a and also mitophagy.
This is further supported by the resveratrol-based study by
Ferretta et al. that also revealed the ability of AMPK to
enhance autophagy flux in parkin-mutant fibroblasts (Fer-
retta et al. 2014). Hence, it is likely that enhanced mito-
chondrial biogenesis and/or mitophagy could help in the
maintenance of a viable pool of bioenergetically competent
mitochondria necessary for dopaminergic neuronal
survival. Accordingly, approaches towards promoting these
processes may be of therapeutic value for PD.
Conclusion
As with many other neurodegenerative diseases, PD is a
debilitating disorder that gradually robs an individual of
his/her fundamental bodily functions. Although much
effort has been put into advancing therapeutic strategies for
this disease, many conventional and existing treatment
options are unfortunately accompanied by several unde-
sirable effects despite their ability to provide symptomatic
relief. Fortunately, with the advent of nutraceuticals, an
alternative avenue to tackle this seemingly evasive bio-
logical problem has been provided. Nutraceuticals, by
virtue of their origin from naturally available food or food
products, appear to be a favourable treatment option since
harnessing therapeutic strategies from natural resources
can potentially avoid side effects. As a matter of fact, many
of the nutraceuticals discussed in this review have been
shown to be not only preventive but also therapeutic for
PD. Significantly, we have highlighted in this paper how
we and others have demonstrated the ability of green tea-
derived catechin EGCG to rescue PD pathological out-
comes, possibly through enhancing mitochondrial
homoeostasis. However, despite many promising reports
about the role of nutraceuticals in neuroprotection for PD,
we acknowledged that it is early days yet as several
mechanistic gaps remain unanswered. Notwithstanding
this, the recognition that nutraceuticals might be of thera-
peutic benefits offers countless opportunities to explore
other natural compounds that have not been looked at in
terms of their potential neuroprotective roles in PD. For
example, ergothioneine (EGT) is a naturally occurring
amino acid found in mushrooms that protects mitochondria
from oxidative stress (Cheah and Halliwell 2012) and was
found to accumulate at significantly lower levels in PD
patients compared to healthy controls (Hatano et al. 2015),
thus suggesting a therapeutic potential of EGT for the
disease. In addition, future research could also direct
efforts towards better understanding the effects of
nutraceuticals in combination with existing drug therapies
for PD patients, in order to derive improved outcomes for
the PD patient. The delivery of nutraceuticals could also be
optimized in order to maximize their neuroprotective
effects. As a parting note, it is hopeful to envisage that one
day we would be able to simply modify our diet to prevent
or mitigate the progression of this debilitating disease.
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